Most importantly, the survival rate for patients with a high level of CCN4 transcripts was markedly lower than that for patients with a low level of CCN4 transcripts (P = 1.2 × 10−8) among solid tumors (breast, lung, and prostate cancer patients) that preferentially metastasize to the brain (Fig. 6g). This evidence concerns the gene CCN4 and prostate carcinoma.